SpendMend Pharmacy Division

Megan Goebig Kussay, RPh., Sabrina Allen, and Eric Howard are heading to Atlanta for the 340B Grantees Conference, October 20–22! Visit Booth #2 to meet our team and learn how SpendMend helps covered entities strengthen compliance and enhance community impact through the 340B Program. We look forward to connecting with fellow 340B leaders and partners!

In this episode, Greg Wilson and Robert Nahoopii, PharmD, MS, ACE chat about what the government shutdown might mean for 340B Program oversight in the short-term. They’ll also discuss a flurry of developments from manufacturers recently. Specifically, they’ll highlight efforts to promote more direct-to-consumer (DTC) pathways for obtaining medications, all related to a recent Trump Administration executive order calling for “most favored nation (MFN)” pricing for drugs in the U.S. SpendMend will be at the 340B Grantee Conference in Atlanta October 20 – 22. Stop by our booth and also catch our presentation at the “Ask the Experts – Open Forum” while you're there!

Matt Parker, PharmD, MHA will be representing SpendMend at the inaugural Med Use Intelligence & Automation (MUIA) track during CPES! We are looking forward to connecting with peers and contributing to this important conversation. See you in Nashville on October 8!

In this episode, Greg Wilson and Robert Nahoopii, PharmD, MS, ACE are joined by SpendMend colleague Heather Lynch, to talk about how H.R.1 (i.e. One Big Beautiful Bill Act, or OBBBA) could impact 340B covered entities in the long run. They’ll discuss how federal Medicaid cuts projected from the bill could influence a trend in lower average DSH% for some hospitals, threatening 340B Program eligibility. They’ll also have a conversation about things hospitals should consider, both in the short term and long term, to brace for the impact. In the intro, they’ll also catch up on various manufacturer actions affecting 340B providers. Email us at 340BUnscripted@spendmend.com with questions and comments!

In this episode, Greg Wilson and Robert Nahoopii, PharmD, MS, ACE review recent changes made to the HRSA Audit Data Request List (DRL). They also discuss some of the comments provided by the public to HRSA regarding potential 340B rebate models, debate a recent change to a manufacturer’s contract pharmacy restrictions, and highlight some communication that has gone out to hospitals regarding a proposed CMS 340B drug acquisition cost survey expected in CY26.   Got questions? Email us at 340BUnscripted@spendmend.com 

In this episode, Greg Wilson and Robert Nahoopii, PharmD, MS, ACE catch up on insights gathered and lessons learned from various forums our team has attended over the last few weeks. Also, they discuss the recently posted FAQ page provided by HRSA in response to questions around the 340B Rebate Model Pilot Program.

A new challenge is threatening 340B eligibility: reductions in Medicare DSH percentages. Nick Gnadt explains the risks and what hospitals can do to prepare. Check out his article in 340B Report below!

Heidi Larson, PharmD will be speaking on Monday, August 25 at the 340B Midwest Regional Conference and Expo! She’ll share insights on compliance challenges, auditing trends, and strategies to ensure HRSA audit readiness.

Stay tuned to 340B Unscripted for more insights as our team continues to navigate the future of 340B rebates.

In this episode, Greg Wilson and Robert Nahoopii, PharmD, MS, ACE discuss tips for completing the annual 340B hospital recertification process, which is occurring now through early September. They also recap a recent notice in the Federal Register that signals HRSA’s intent on modifying some elements of OPAIS and the 340B enrollment/registration/recertification process. The guys also can’t help themselves and wrap up with another debate around impending 340B rebate considerations. Proposed OPAIS changes: https://lnkd.in/eNzWmSGS   Register for our Trulla webinar on August 26th: https://lnkd.in/gdA4vb-G